A detailed history of Janus Henderson Group PLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 2,478,160 shares of MDGL stock, worth $770 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares
2,478,160
Previous 2,485,751 0.31%
Holding current value
$770 Million
Previous $696 Million 24.48%
% of portfolio
0.28%
Previous 0.38%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$212.22 - $292.96 $1.61 Million - $2.22 Million
-7,591 Reduced 0.31%
2,478,160 $526 Million
Q2 2024

Aug 14, 2024

SELL
$193.33 - $291.99 $22.3 Million - $33.7 Million
-115,531 Reduced 4.44%
2,485,751 $696 Million
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $51.5 Million - $85.2 Million
-300,768 Reduced 10.36%
2,601,282 $695 Million
Q4 2023

Feb 14, 2024

SELL
$120.4 - $237.13 $16.9 Million - $33.3 Million
-140,611 Reduced 4.62%
2,902,050 $671 Million
Q3 2023

Nov 14, 2023

BUY
$146.04 - $225.78 $228 Million - $352 Million
1,558,535 Added 105.01%
3,042,661 $444 Million
Q2 2023

Aug 14, 2023

BUY
$203.88 - $312.0 $226 Million - $346 Million
1,108,452 Added 295.06%
1,484,126 $343 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $44.6 Million - $59.3 Million
193,026 Added 105.68%
375,674 $91 Million
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $5.62 Million - $28.5 Million
96,265 Added 111.44%
182,648 $53 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $5.23 Million - $6.87 Million
86,383 New
86,383 $5.61 Million
Q4 2018

Feb 06, 2019

SELL
$94.77 - $215.54 $127,276 - $289,470
-1,343 Closed
0 $0
Q3 2018

Nov 09, 2018

BUY
$207.3 - $300.31 $94,114 - $136,340
454 Added 51.07%
1,343 $288,000
Q2 2018

Aug 10, 2018

BUY
$101.55 - $313.9 $90,277 - $279,057
889 New
889 $249,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.32B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.